Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Total Non-Current Liabilities data on file, last reported at $16.5 billion in Q2 2026.

• Quarterly Total Non-Current Liabilities fell 23.24% year-over-year to $16.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.5 billion (down 23.24% YoY) and the FY2025 annual result came in at $19.4 billion, down 6.87% from the prior year.
• Total Non-Current Liabilities declined to $16.5 billion in Q2 2026, from $18.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $25.2 billion in Q1 2022 to a low of $16.5 billion in Q2 2026.
• A 5-year average of $22.0 billion and a median of $21.7 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities increased 0.44% — and 2026, when it retreated 23.24%.
• Tracing TEVA's Total Non-Current Liabilities over 5 years: stood at $23.9 billion in 2022, then declined by 3.5% to $23.1 billion in 2023, then slipped by 9.94% to $20.8 billion in 2024, then dropped by 6.87% to $19.4 billion in 2025, then dropped by 15.09% to $16.5 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $16.5 billion (Q2 2026), $18.3 billion (Q1 2026), and $19.4 billion (Q4 2025), per Business Quant data.